[Antiphospholipid antibodies in Behcet's disease].

Novel functional activities of anti-DNA autoantibodies from sera of patients with lymphoproliferative and autoimmune diseases. Appl Biochem Biotechnol (1998) 0.96

Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database. J Rheumatol (2010) 0.96

Ovarian function and disease activity in patients with systemic lupus erythematosus. Clin Exp Rheumatol (2008) 0.92

[C-reactive protein--marker of inflammation in atherosclerosis (new data)]. Kardiologiia (2002) 0.88

[Investigation of mechanisms of neuro-protective effect of semax in acute period of ischemic stroke]. Zh Nevrol Psikhiatr Im S S Korsakova (1999) 0.87

Molecular pathogenesis of systemic lupus erythematosus. Arch Virol (1975) 0.85

Anti-DNA autoantibodies reveal toxicity to tumor cell lines. Immunol Lett (2002) 0.85

Lack of association between three vascular endothelial growth factor gene polymorphisms and systemic sclerosis: results from a multicenter EUSTAR study of European Caucasian patients. Ann Rheum Dis (2006) 0.83

[Neopterin: new immunological marker of autoimmune rheumatic disease]. Klin Med (Mosk) (2000) 0.83

DNA-specific antiidiotypic antibodies in the sera of patients with autoimmune diseases. FEBS Lett (1992) 0.83

Endocarditis with left atrial thrombus formation in Behçet's disease mimicking myxoma. J Rheumatol (1993) 0.82

[Cardiolipin antibodies in acute rheumatic fever]. Klin Med (Mosk) (1992) 0.82

[Evaluation of methotrexate effect on the acute-phase response in rheumatoid arthritis after 12-week treatment]. Klin Med (Mosk) (2014) 0.82

[Anti-phosphatidylethanolamine antibodies in patients with Sneddon's syndrome]. Klin Med (Mosk) (2005) 0.82

[The efficiency and safety of adalimumab treatment in patients with active rheumatoid arthritis unresponsive to standard therapy: Russian national study results]. Ter Arkh (2012) 0.81

[Antibodies to various phospholipids in SLE patients with primary antiphospholipid syndrome]. Klin Med (Mosk) (1999) 0.81

[Prevalence of mental disorders in SLE patients: correlations with the disease activity and comorbid chronic conditions]. Ter Arkh (2009) 0.80

[Cardiolipin antibodies in patients with myocardial infarction and unstable angina pectoris]. Kardiologiia (1992) 0.80

C3a and C5a anaphylatoxins bind to heparin-based sorbent in low density lipoprotein apheresis: in vitro and in vivo investigations. Artif Organs (1992) 0.80

[Cardiac rhythm and conduction disorders in polymyositis and dermatomyositis]. Klin Med (Mosk) (1998) 0.80

[Effect of small-dose glucocorticoids on the course of early rheumatic arthritis]. Klin Med (Mosk) (2004) 0.79

[Effect of exogenous interferon and various interferon inducers on the indicators of general reactivity in systemic lupus erythematosus]. Ter Arkh (1980) 0.79

[Magnetophoresis and magnetic susceptibility of HeLa tumor cells]. Biofizika (2006) 0.79

[Structum (chondroitin sulfate)--a new agent for the treatment of osteoarthrosis]. Ter Arkh (1999) 0.78

[Atherogenic cholesterol-containing circulating immune complexes--one of the components of the serum in patients with systemic lupus erythematosus]. Klin Med (Mosk) (2003) 0.78

[The HLA-B5 immunogenetic marker in Behçet's disease]. Ter Arkh (1993) 0.78

[Characteristics of retinal vascular involvement in systemic lupus erythematosus]. Vestn Oftalmol (2001) 0.78

[Serum neopterin in hepatitis B]. Klin Med (Mosk) (1992) 0.78

[New approaches to pharmacotherapy for rheumatoid arthritis: perspective for use of tocilizumab (monoclonal antibodies to interleukin-6 receptor)]. Ter Arkh (2010) 0.78

[Clinical significance of determining antibodies to poly A: poly U in systemic lupus erythematosus]. Ter Arkh (1972) 0.78

[Catalytic autoantibodies--a new molecular instrument in cardiology and ophthalmology]. Ter Arkh (2006) 0.78

[Cardiovascular diseases in rheumatoid arthritis]. Ter Arkh (2007) 0.77

[The magnitude of fatigue and its association with depression, pain, and inflammatory activity in rheumatoid arthritis]. Ter Arkh (2013) 0.77

[Clinical implication of assessment of heart rate variability in patients with psoriatic arthritis]. Ter Arkh (2009) 0.77

[The importance of cytokine profile characteristics for evaluating the therapeutic effectiveness of monoclonal antibodies against IL-6 receptors in patients with rheumatoid arthritis]. Klin Med (Mosk) (2014) 0.77

[The von Willebrand factor antigen in patients with rheumatoid arthritis: a method for its determination and the clinical significance]. Ter Arkh (1993) 0.77

[Role of antiphospholipid antibodies in occlusion of retinal vessels in various vascular eye diseases]. Vestn Oftalmol (2002) 0.77

[Efficacy of colloid bismuth subcitrate (De-Nol) in gastropathies induced by nonsteroid anti-inflammatory drugs: an open controlled 4-week trial]. Ter Arkh (2005) 0.77

[Serum nitrates in patients with systemic lupus erythematosus and antiphospholipid syndrome]. Ter Arkh (2004) 0.77

[Behçet's disease: clinical and demographic associations]. Ter Arkh (2013) 0.77

[Relationship of the clinical efficiency of tocilizumab therapy to the serum level of matrix metalloproteinase-3 in patients with rheumatoid arthritis]. Ter Arkh (2013) 0.77

[Prospects for the assessment of cardiac rhythm variability in patients with rheumatoid arthritis and systemic lupus erythematosus]. Vestn Ross Akad Med Nauk (2010) 0.77

[Cardiological aspects of the antiphospholipid syndrome. Part I. Valvular lesions in the primary and secondary antiphospholipid syndrome and systemic lupus erythematosus]. Kardiologiia (2002) 0.77

Anticardiolipin antibodies in Sneddon's syndrome. Neurology (1990) 0.76

[Cognitive impairment and anxiety-depressive disorders in patients with rheumatoid arthritis]. Zh Nevrol Psikhiatr Im S S Korsakova (2012) 0.76

[Soluble CD40 ligand in systemic lupus erythematosus and antiphospholipid syndrome]. Ter Arkh (2006) 0.76

[The clinical significance of neopterin in human diseases]. Ter Arkh (1993) 0.76

[Soluble receptors of TNF-alpha in rheumatoid arthritis]. Klin Med (Mosk) (2001) 0.76

[Markers of chronic inflammation in patients with ischemic heart disease with in-stent restenosis]. Kardiologiia (2005) 0.76

Sneddon's syndrome: cardiac pathology and antiphospholipid antibodies. Clin Exp Rheumatol (1991) 0.76

[Autoantibodies Against beta(1)-Adrenoreceptors in Patients With Cardiac Rhythm Disorders. Prevalence and Possible Role in Development of Arrhythmia]. Kardiologiia (2004) 0.76

[Antibodies to beta2-glycoprotein I in systemic lupus erythematosus: new laboratory marker of antiphospholipid syndrome]. Klin Med (Mosk) (1998) 0.76

[Soluble receptors of TNF-alpha with molecular mass 55 kDa in rheumatoid arthritis: clinical role]. Klin Med (Mosk) (2003) 0.76

[Evaluation of the efficacy and tolerance of ibandronic acid in patients with osteoarthrosis in the knee joints concurrent with osteoporosis: a pilot study]. Ter Arkh (2013) 0.76

[The functional activity and count of the natural killer cells in patients with recently diagnosed diabetes mellitus types I and II]. Ter Arkh (1989) 0.76

[Soluble adhesion molecules (P-selectin, ICAM-1 and ICAM-3) in rheumatoid arthritis]. Ter Arkh (1999) 0.76

[Subclinical and clinical manifestations of atherosclerosis in antiphospholipid syndrome]. Ter Arkh (2008) 0.76

[Sneddon's syndrome and the primary antiphospholipid syndrome]. Ter Arkh (1993) 0.76

[Isolation and characteristics of catalytic antibodies to DNA in systemic lupus erythematosis]. Biokhimiia (1993) 0.76

[The role of estrogen-androgen imbalance in rheumatic diseases]. Ter Arkh (1990) 0.76

[DNA-abzymes in rheumatoid arthritis: pathogenetic and clinical significance]. Ter Arkh (2005) 0.76

[Differential diagnosis of Wegener's granulomatosis and extranodal NK/T-cell lymphoma, nasal type]. Ter Arkh (2012) 0.76

[Pharmacotherapy of rheumatoid arthritis: the 21st century]. Klin Med (Mosk) (2005) 0.75

Endothelial inclusions and "nuclear bodies" in systemic lupus erythematosus. Ann Rheum Dis (1973) 0.75

[The renin-angiotensin-aldosterone system and arterial hypertension in patients with rheumatoid arthritis]. Klin Med (Mosk) (1991) 0.75

[Combined medication ARTRA in the treatment of osteoarthrosis]. Ter Arkh (2005) 0.75

[Place of hemocarboperfusion and hyperbaric oxygenation in the treatment of patients with rheumatoid arthritis with systemic symptoms]. Ter Arkh (1986) 0.75

[Activation of latent infections caused by the Epstein-Barr virus in systemic lupus erythematosus]. Revmatologiia (Mosk) (1986) 0.75

[Study of pirprofen (rengasil) combined with maintenance doses of corticosteroids in rheumatoid arthritis in a double-blind multicenter trial]. Ter Arkh (1986) 0.75

[Viruses and collagenoses]. Vopr Revm (1981) 0.75

[Optic neuritis in systemic lupus erythematosus (personal case and review of the literature)]. Revmatologiia (Mosk) (1986) 0.75